ORIGINAL ARTICLE
Use of Medihoney as a non-surgical therapy for chronic pressure ulcers in patients with spinal cord injury

B Biglari1, PH vd Linden2, A Simon3, S Aytac2, HJ Gerner4 and A Moghaddam2

Study design: Prospective, observational study of 20 spinal cord-injured (SCI) patients with chronic pressure ulcers (PUs) using Medihoney.

Objectives: To determine the effects of Medihoney by bacterial growth, wound size and stage of healing in PUs.

Methods: We treated 20 SCI adult patients with chronic PUs using Medihoney. In all, 7 patients (35%) were female, and 13 (65%) were male. The average patient age was 48.7 years (30–79). In all, 6 patients (30%) were tetraplegic and 14 (70%) were paraplegic. Also, 5 patients (25%) had grade IV ulcers and 15 patients (75%) had grade III ulcers according to the National Pressure Ulcer Advisory Panel.

Results: After 1 week of treatment with Medihoney, all swabs were void of bacterial growth. Overall 18 patients (90%) showed complete wound healing after a period of 4 weeks, and the resulting scars were soft and elastic. No negative effects were noted from the treatment using Medihoney. No blood sugar level derailment was documented.

Conclusion: The medical-honey approach to wound care must be part of a comprehensive conservative surgical wound-care concept. Our study indicates the highly valuable efficacy of honey in wound management and infection control as measured by bacterial growth, wound size and healing stage.

Keywords: pressure ulcer; paraplegics; MRSA; spinal cord-injured; Medihoney; medical honey

INTRODUCTION
Pressure ulcers (PUs) are among the most common complications in patients with spinal cord injury.1,2 In Europe, the medical treatment costs of patients with PUs are 2.5 times higher than the treatment costs of patients without PUs. Current reports show an increasing incidence of PUs: 9.2% in 1989, 15.5% in 2003 and 10% in 2004.3

The long-term immobilisation and the lack of innervation result in muscle atrophy and lead to a decrease in the soft tissue coverage of bony structures. The remaining soft tissue, which is reduced in thickness, can no longer withstand the pressure and, in conjunction with poor wound healing, a PU may result.

Similarly, the emergence of decubitus is promoted by the absent sensitive innervation of the skin, because, due to this, the patient concerned fails to notice the progression of the PU. The main problem in clinical practice is the deep and extended soft tissue damage and necrosis and the bacterial super infection. These are not only a challenge for the surgeon, but can also lead to life-threatening complications.

PU is a lifelong health risk for paraplegic patients and can recur. Therefore, in order to withstand this, they require intensive care and modern technical equipment. Because of the need for lifelong therapy, the surgical procedure must be planned in advance and carefully. Here additive methods could be helpful.

The decision regarding surgical or non-surgical closure of ulcers depends on the size, depth, localisation, bacterial colonisation of the defect, the age and the general health of the patient, as well as on the duration of existence of the PU. Dry necrosis is debrided surgically. Wound dressings should absorb surplus secretions, facilitate gas exchange, form a barrier to microorganisms and be readily removable. Further therapies include enzymatic cleaning and the application of hydrocolloidal plates or hydroactive dressings such as Alginate, with the shared goal of obtaining optimal wound healing.

With hospitals facing the problem of increasing bacterial resistance and presence of biofilms,4 it is important to have antiseptic concepts. In this manner, an ideal wound antiseptic should meet the following criteria:5

- A rapid onset of bactericidal action and a remnant broad-spectrum effect against bacteria and fungi, even under the unfavourable conditions of exuding colonised or infected wounds.
- Enhancement and acceleration of the physiological process of wound healing (debridement, granulation), even if applied for prolonged periods.
- No adverse local or systemic effects (allergy, toxicity related to absorption).
- A moderate cost even if applied two times daily.

This report represents a series of professional wound care with medical-grade honey in spinal cord-injured (SCI) patients with PUs.

MATERIALS AND METHODS
This study was a nine-centre, prospective, observational and open-label study, conducted between March 2007 and March 2009. It was initiated and...
coordinated by the Department of Paediatric Haematology and Oncology at the University Hospital of Bonn. Financial support was obtained from the manufacturer of the Medihoney products, who did not have any influence on data collection, analysis or publication parameters.

Ethical approval was gained for this study from the Ethics Committee of the Medical Faculty of the Rheinische Friedrich-Wilhelms-University of Bonn (No. 025/05); this approval was applied to all participating centres. In our Center (Department of paraplegiologie of BG Trauma centre in Ludwigshafen, Germany), we participated from January 2008 to November 2008 in this study. In all, 20 adult patients with chronic PUs and spinal cord injuries of different levels received Medihoney treatment for more than 6 weeks. The PUs differed in size, depth, grade and bacterial colonisation. Each patient had previously undergone unsuccessful PU treatment with alternate dressings for a minimum of 12 weeks. The Medihoney dressings were changed daily in a sterile environment. Overall, 7 patients (35%) were female and 13 (65%) were male. The average age was 48.7 years (30–79). A total of 6 patients (30%) were tetraplegic and 14 (70%) were paraplegic. Overall, 15 patients (75%) were completely paralysed and 5 patients were (25%) incompletely paralysed. In all, 5 patients (25%) had grade IV ulcers, and 15 patients (75%) had grade III ulcers according to the National Pressure Ulcer Advisory Panel classification. All patient wounds were documented with weekly photographs.

The honey used for this study was Medihoney antibacterial honey (Comvita, New Zealand), which is listed on the Australian Register of Therapeutic Goods for the treatment of acute and chronic wounds. This honey has been gamma-irradiated to kill clostridium spores without affecting the in vitro anti-bacterial effect of the honey. The Medihoney dressings were prepared by application of the honey to a non-adherent sterile contact layer that was placed on top of a sterile dressing pad. The honey was applied at a thickness of approximately 3 mm and conformed to the shape of the ulcers.

RESULTS

We treated 20 SCI adult patients with chronic PUs of different sizes, depths, grades and degrees of bacterial colonisation with Medihoney from January 2008 until November 2008. In all, 7 patients (35%) were female, and 13 (65%) were male. The average patient age was 48.7 years (30–79). A total of 6 patients (30%) were tetraplegic and 14 (70%) were paraplegic. Overall, 15 patients (75%) were completely paralysed, and 5 (25%) were partially paralysed.

Table 1 shows the levels of spinal cord damage, ulcer localisation, size, age, sex, wound colonisation and ulcer grade.

All patients treated with Medihoney had suffered from 1–2 chronic PUs for more than 3 months; 5 patients (25%) had grade IV ulcers, and 15 (75%) had grade III ulcers. In all patients, the wound surface was measured using square transparent films that measured 0.5 ≤ 0.5 cm². The average PU size was 21.7 cm² (8–80 cm²).

A total of 5 patients (25%) underwent surgical necroscopy owing to very dry necrosis. The ulcer locations were sacral (45%), leg (20%), heel (10%), ischial (15%), groin (5%) and thigh (5%). Sterile swabs of the wound surface were taken daily using standard microbiological culture methods (Figures 1a–c).

During treatment with Medihoney, PUs were documented at 3-week intervals. During the examinations, the ulcers were photographed, measured and cultured. All PUs were treated once daily with Medihoney after being cleaned with sterile Ringer’s solution. The surrounding skin was disinfected with either Octenisept (Octenidin-hydrochloride 0.1%, Phenoxyethanol 3%; Schülke, Norderstedt, Germany) or Octeniderm (Octenidinhydrochloride 0.1 Vol%, 1-Propanol 30 Vol%, 2-Propanol 45 Vol%; Schülke). Care was taken to avoid contact between the wound surface and the disinfectant. No antibiotic treatment was given simultaneously to the Medihoney treatment to avoid any outside influences on the therapeutic effect of the honey.

After 1 week of treatment with Medihoney, all swabs were void of bacterial growth. A total of 18 patients (90%) showed complete wound healing after a period of 4 weeks. Resulting scars were soft and elastic (Figures 2a–c and 3a–c). No negative effects were noted from treatment with Medihoney. No blood sugar level derailing was documented in diabetic patients, despite the daily application of large amounts of honey. No allergic reactions were noted.

DISCUSSION

Our study, the first comprehensive case series of 20 SCI adult patients with chronic PUs, demonstrates the feasibility and effectiveness of

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Lesion level</th>
<th>Localisation</th>
<th>Frankel</th>
<th>Grading</th>
<th>Bacterial colonisation</th>
<th>Size</th>
<th>Age (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>Th4</td>
<td>Sacrum</td>
<td>A</td>
<td>III</td>
<td>Staph. epi.</td>
<td>35</td>
<td>79</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>Th1</td>
<td>Ischium and scrotal</td>
<td>B</td>
<td>III</td>
<td>Klebs. Pneumo.</td>
<td>80</td>
<td>35</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>Th12</td>
<td>Heel</td>
<td>A</td>
<td>III</td>
<td>Staph. aur., Pseud. aeru.</td>
<td>8</td>
<td>78</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>Th8</td>
<td>Leg</td>
<td>A</td>
<td>IV</td>
<td>Enterb. cloa., Prot. mib., Staph. aur.</td>
<td>50</td>
<td>44</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>C7</td>
<td>Sacrum</td>
<td>B</td>
<td>III–IV</td>
<td>Staph. epi., Hae. str. gr. F Klebs, Pseud. aeru.</td>
<td>19</td>
<td>50</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>Th1</td>
<td>Leg</td>
<td>A</td>
<td>III</td>
<td>MRSA</td>
<td>30</td>
<td>35</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>L1</td>
<td>Ankle</td>
<td>A</td>
<td>III</td>
<td>MRSA</td>
<td>20</td>
<td>51</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>L1</td>
<td>Sacrum</td>
<td>A</td>
<td>III</td>
<td>MRSA</td>
<td>15</td>
<td>51</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>Th11</td>
<td>Sacrum</td>
<td>B</td>
<td>III–IV</td>
<td>Entcoc., Prot. mib., E.coli.</td>
<td>12</td>
<td>30</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>Th11</td>
<td>Ischium</td>
<td>A</td>
<td>III</td>
<td>E.coli., Staph. aur.</td>
<td>10</td>
<td>49</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>Th10</td>
<td>Sacrum</td>
<td>A</td>
<td>III</td>
<td>E. coli.</td>
<td>12</td>
<td>58</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>Th12</td>
<td>Sacrum</td>
<td>A</td>
<td>III–IV</td>
<td>E. coli.</td>
<td>10</td>
<td>52</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>L1</td>
<td>Sacrum</td>
<td>A</td>
<td>III</td>
<td>MRSA</td>
<td>10</td>
<td>52</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>C7</td>
<td>Abdomen</td>
<td>A</td>
<td>III</td>
<td>Staph. epi.</td>
<td>10</td>
<td>33</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>C7</td>
<td>Thigh</td>
<td>A</td>
<td>III</td>
<td>Staph. epi.</td>
<td>20</td>
<td>33</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>C7</td>
<td>Groin, ischium</td>
<td>A</td>
<td>IV</td>
<td>Pseud. aeru.</td>
<td>10</td>
<td>50</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>Th10</td>
<td>Leg</td>
<td>A</td>
<td>III</td>
<td>Enterb. cloa., Prot. mib.</td>
<td>20</td>
<td>42</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>L1</td>
<td>Sacrum</td>
<td>B</td>
<td>III</td>
<td>MRSA</td>
<td>15</td>
<td>45</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>C5</td>
<td>Heel</td>
<td>B</td>
<td>III</td>
<td>Pseud. aeru.</td>
<td>20</td>
<td>40</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>L1</td>
<td>Sacrum</td>
<td>A</td>
<td>III</td>
<td>MRSA</td>
<td>30</td>
<td>50</td>
</tr>
</tbody>
</table>

**Abbreviations:** Entcoc., Enterococcus; Enterb. Cloa., Enterobacter cloacae; E. coli., Escherichia coli; F, female; Klebs. Pneumo., Klebsiella pneumoniae; M, male; MRSA, Methicillin-resistant Staphylococcus aureus; Prot. mib., Proteus mirabilis; Provid. stuwri., Providencia stuartii; Pseud. aeru., Pseudomonas aeruginosa; Staph. aur., Staphylococcus aureus; Staph. epi., Staphylococcus epidermidis.
medical honey wound treatment as one of many different therapeutic approaches.

Although additional prospective randomised studies on a variety of wounds are needed to confirm the safety and efficacy of medical honey, our study is consistent with current evidence\(^7\)\(^9\) that confirms the antibacterial properties and additional beneficial effects of medical honey on wound healing. The positive results of this study should encourage other wound-care professionals to implement the use of CE-certified honey dressings with standardised antibacterial activity into their professional wound-care regimen.

The available evidence indicates effective treatment for wound care. Reports from 17 randomised controlled trials involving a total of 1965

---

**Figure 1** Patient number 1 (Table 1). A 79-year-old male paraplegic (Th4) patient with sacral ulcer grade 3 NPUAP\(^6\) (a) First photo documentation. (b) Second photo, 2 weeks after Medihoney treatment. (c) Third photo, 4 weeks after Medihoney treatment.

**Figure 2** Patient number 2 (Table 1). A 35-year-old male paraplegic (Th1) patient with ischial and scrotal ulcer grade 3–4 NPUAP\(^6\) (a) First photo documentation. (b) Second photo, after primary surgical debridement and 2-week Medihoney treatment. (c) Third photo, 4 weeks after Medihoney treatment.
participants and 5 clinical trials of other forms involving 97 participants, collectively demonstrate that honey is an effective treatment for wounds.

In addition, there is a large amount of supporting evidence for the use of honey in wound care from case studies. Clinicians often view honey as a novel and experimental wound treatment despite the large amount of evidence that establishes honey as a tested, safe and effective therapy. Clinicians who dismiss honey as non-scientific or not well-researched are encouraged to look for clinical evidence supporting the standard treatment they usually rely upon.

At the beginning of the honey treatment in our study, all PUs showed colonisation with various bacterial pathogens (Table 1). After 1 week of treatment with Medihoney, no residual bacteria were detected in wound swabs; even the decubitus initially colonised with Methicillin-resistant Staphylococcus aureus was effectively decolonised with Medihoney. Our study clearly demonstrated the antibacterial properties of honey by clearing the infections from all the PUs to which it was applied. The honey we used is known to have enhanced antibacterial action and has been shown in other clinical case studies to disinfect the wound and improve clinical wound healing.\(^\text{10}\)

Dunford et al.\(^\text{11}\) conducted a four-centre feasibility study to determine whether Medihoney was an acceptable treatment for patients with leg ulcers in terms of pain relief, odour control and overall patient satisfaction. A total of 40 patients, whose leg ulcers had not responded to 12 weeks of compression therapy, were recruited. Medihoney dressings were applied to their ulcers for a 12-week study period. All other aspects of their care, including the use of compression bandaging, remained unchanged. Overall, ulcer pain and size decreased significantly, and odorous wounds were deodorised promptly with Medihoney treatment. Conversely, Jull et al.\(^\text{12}\) found that for chronic venous leg ulcers, honey did not significantly decrease the healing time, when used with compression bandaging. Further studies are needed to clarify the role of honey as an adjuvant therapy in the management of venous ulcers. In large acute wounds, such as burn wounds, however, Jull et al.\(^\text{12}\) concluded that honey might reduce healing time compared with some conventional dressings.

In the superficial and partial thickness wounds caused by burn injuries, honey has been shown to improve healing times.\(^\text{10,12}\) Wijesinghe et al.\(^\text{1}\) compared burns covered with a honey gauze with those covered with silver sulphadine-impregnated gauze in 624 subjects, with the primary end point being healing at 15 days. Honey proved to be more effective than silver, with a fixed effect odds ratio of 6.1 for healing at 14 days (95% CI 3.7–9.9). Silver was significantly less effective in all secondary outcome measures.\(^\text{10,12}\)

Medical honey dressings are non-adherent after rinsing with sterile Ringer’s solution, easy to change without pain, and do not cause harm to the regenerating tissue. Malodour from recalcitrant wounds, as a result of critical colonisation and partial tissue necrosis, is successfully abolished with medical honey due to its antibacterial, anti-inflammatory and debriding effects. Medical honey can be used in all stages of wound healing, in many different types of wounds, and even in patients with diabetes.

Certainly, the medical honey approach to wound care must be part of a comprehensive, conservative and surgical wound-care concept. Patients with extended tissue necrosis require surgical debridement before medical honey is used. In patients with deep local soft tissue or with systemic infection, appropriate antimicrobial treatment is necessary in addition to local wound care.

Further, any comorbidity that contributes to the problems in wound healing should be diagnosed and treated thoroughly with state-of-the-art interventions (for example, bypass surgery in patients with reduced arterial perfusion, compressive bandages in patients with chronic venous ulcers, and sufficient control of blood glucose levels in patients with diabetic foot syndrome).

CONCLUSION

Our study, a clinical trial documenting wound healing with honey treatment as measured by bacterial growth, wound size and
stage of healing, indicates that honey is highly effective in wound management.

Although minimal evidence can be found to discourage or restrict the application of medical honey to wounds, more studies are needed to establish universal clinical medical honey guidelines with regard to the size, type and age of the wounds best treated with medical honey to assure long-term safety and efficacy, and to uncover possible contraindications.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
We thank Dr Ralph Hanano, who has been an authorised wound-care specialist representing Comvita, the manufacturer of Medihoney products during the study period in Germany. The study has been funded by a scientific grant from Comvita.


7 Molan PC. The evidence supporting the use of honey as a wound dressing. Int J Low Extrem Wounds 2006; 5: 40–54.


